The lead program of the company is TTI-621 which is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. Press Release reported on 02/03/21 that An Aging Population is Increasing the Need for Novel Treatments. About TRIL. "Trillium Therapeutics Inc is a Canadian clinical stage immuno-oncology company which is engaged in developing therapies for the treatment of cancer. Trillium Therapeutics NASDAQ Updated Mar 15, 2021 11:59 PM. Trillium Therapeutics news and TRIL price. Post-Market 0.01 (0.09%) Trillium Therapeutics Inc. (NASDAQ:TRIL) went down by -7.81% from its latest closing price compared to the recent 1-year high of $20.96. Trillium Therapeutics, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Shares of the clinical-stage immuno-oncology company Trillium Therapeutics (NASDAQ:TRIL) jumped by as much as 40% in pre-market trading Wednesday morning. The company’s stock price has collected 11.12% of gains in the last five trading sessions. TRIL 11.09 0.94 (7.81%). The company report on February 2, 2021 that PIMCO Closed-End Funds Declare Monthly Common Share Distributions.. Get the hottest stocks to trade every day before the market opens 100% free. What happened. Find the latest news headlines from Trillium Therapeutics Inc. Common Shares (TRIL) at Nasdaq.com. A high-level overview of Trillium Therapeutics Inc. (TRIL) stock. To see how Trillium Therapeutics Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: TRIL stock’s performance was -2.71% in the latest trading, and +267.01% in the past year, while Zoetis Inc Cl A (ZTS) has traded +0.12% on the day and positioned +44.83% higher than it was a year ago. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Free real-time prices, trades, and chat. 5 Biotech … Trillium Therapeutics Inc. [NASDAQ: TRIL] loss -7.81% or -0.94 points to close at $11.09 with a heavy trading volume of 2561109 shares. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, recently presented at the American Society of Hematology (ASH) Annual Meeting, taking place virtually from December 5-8, 2020, and provides … RTTNews 40d. News for Trillium Therapeutics Inc. Pfizer Invests $120 Million In Four Clinical-stage Biotech Companies In H2 2020 - Quick Facts .